Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ensovibep  COVID-19 treatment studies for Ensovibep  C19 studies: Ensovibep  Ensovibep   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Novartis (RCT) 89% 0.11 [0.01-2.27] death 0/301 2/99 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.15 Early treatment 89% 0.11 [0.01-2.27] 0/301 2/99 89% improvement ACTIV-3 (RCT) 0% 1.00 [0.50-2.00] recovery n/a n/a FUTILITY, PENDING​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.50-2.00] 0% improvement All studies 45% 0.55 [0.08-3.76] 0/301 2/99 45% improvement 2 ensovibep COVID-19 studies c19early.com/ev Jan 16, 2022 Tau​2 = 1.18, I​2 = 48.4%, p = 0.56 Effect extraction pre-specified 1 FUTILITY: terminated for futility, results pending Favors ensovibep Favors control
Ensovibep COVID-19 studies. Ensovibep requires IV infusion, but may be less variant dependent than monoclonal antibodies. Recently added: Rothenberger Molecular Partners Novartis. Submit updates/corrections.
Jan 10
Early Novartis Press Release (News)
death, ↓89.0%, p=0.06
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
Details   EMPATHY Part A RCT with 407 patients, 301 treated with ensovibep, showing statistically significant viral load reduction (details not provided), and lower mortality and hospitalization. For discussion see [1].
Nov 16
Late Molecular Partners, Press Release (News)
recovery, 0.0%, p=1.00
Molecular partners provides update from ACTIVE-3 global clinical study of ensovibep in patients hospitalized with COVID-19
Details   News release reporting that ensovibep was terminated for futility in ACTIV-3. 470 patients had been randomized.
Feb 3
In Vitro Rothenberger et al., bioRxiv, doi:10.1101/2021.02.03.429164 (Preprint) (In Vitro)
In Vitro
Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants
Details   In Silico, In Vitro, and hamster study of ensovibep, a DARPin candidate that can engage all three units of the spike protein trimer to inhibit ACE2 interaction, showing efficacy for common variants, and efficacy comparable to casirivimab/..
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit